Nanomedicines Targeting Respiratory Injuries for Pulmonary Disease Management
Advanced Functional Materials
; 2022.
Article
in English
| Scopus | ID: covidwho-1729090
ABSTRACT
The respiratory system holds crucial importance in the biology of vertebrate animals. Injuries of the respiratory system caused by viral infections (e.g., by COVID-19, MERS, and SARS) can lead to severe or lethal conditions. So far there are no effective treatments for respiratory injuries. This represents a highly unmet clinical need, e.g., during the current COVID-19 pandemic. Nanomedicines have high potential in the treatment of respiratory injuries. In this review, the pathology and clinical treatments of major respiratory injuries, acute lung injury, and acute respiratory distress syndrome are briefly summarized. The review primarily focuses on nanomedicines based on liposomes, solid lipid nanoparticles, polymeric nanoparticles, and inorganic nanoparticles, which are tested in preclinical models for the treatment of respiratory injuries. These nanomedicines are utilized to deliver a variety of therapeutic agents, including corticosteroids, statins, and nucleic acids. Furthermore, nanomedicines are also investigated for other respiratory diseases including chronic obstructive pulmonary disease and asthma. The promising preclinical results of various nanoformulations from these studies suggest the potential of nanomedicines for future clinical management of respiratory viral infections and diseases. © 2022 The Authors.
acute lung injury; acute respiratory distress syndrome; COVID-19; nanomedicine; respiratory injury; Biological organs; Liposomes; Nanoparticles; Nucleic acids; Phospholipids; Pulmonary diseases; Respiratory system; 'current; Clinical treatments; Disease management; High potential; Lethal conditions; Viral infections; Medical nanotechnology
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Language:
English
Journal:
Advanced Functional Materials
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS